Effects of stratification on data mining in the US vaccine adverse event reporting system (VAERS)

被引:39
|
作者
Woo, Emily Jane [1 ]
Ball, Robert [1 ]
Burwen, Dale R. [1 ]
Braun, M. Miles [1 ]
机构
[1] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA
关键词
D O I
10.2165/00002018-200831080-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccines are administered differentially according to age and sex, and disease patterns also vary among people of different age and sex groups. Estimates of disproportionality should be calculated based on comparisons of groups that have a similar likelihood of receiving similar vaccines and experiencing similar adverse events, to prevent false disproportionality from occurring. Stratified empirical Bayesian (EB) methods have been compared with crude, but not stratified, proportional reporting ratios (PRRs) in their performance on adverse event data. Objectives: (i) to implement stratification of PRR; (ii) to quantify and compare vaccine-event pairs that are highlighted by PRR and EB05 (the lower bound of the 90% CI of the EB geometric mean), for both crude and stratified; and (iii) to evaluate the effects of stratification by age and sex, in identifying adverse events that are accepted to be caused by vaccines. Methods: We applied EB and PRR data mining methods to data from the US Vaccine Adverse Event Reporting System (VAERS). We stratified PRR and EB05 by age and sex. To study the effects of stratification, we compared the crude PRR and stratified PRR. We also assessed the crude EB05 and stratified EB05, and then compared the effects of stratification on EB05 and PRR. Results: Stratification not only changed the number of vaccine-event pairs that were highlighted, but also changed which pairs were highlighted. There were 283 vaccine-event pairs that were highlighted by the crude EB05, but not the stratified; 12 that were highlighted by the stratified EB05, but not the crude; and 162 that were highlighted by both. Similarly, there were 701 vaccine-event pairs that were highlighted by the crude PRR, but not the stratified; 139 that were highlighted by the stratified PRR, but not the crude; and 895 that were highlighted by both. There were 1466 vaccine-event pairs in which the effect of stratification was different for EB05 and PRR. Conclusion: To our knowledge, this is the first published analysis using stratified PRRS. In this analysis of passive surveillance data, stratification revealed and reduced confounding in EB and PRR, and also unmasked some vaccine-event pairs that the crude values did not highlight. Stratification should be applied if confounding is suspected. By decreasing the total number of highlighted vaccine-event pairs, stratification is likely to increase efficiency and therefore might reduce workload.
引用
收藏
页码:667 / 674
页数:8
相关论文
共 50 条
  • [21] The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barre syndrome
    Miller, Elaine R.
    McNeil, Michael M.
    Moro, Pedro L.
    Duffy, Jonathan
    Su, John R.
    [J]. VACCINE, 2020, 38 (47) : 7458 - 7463
  • [22] THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS) (VOL 12, PG 542, 1994)
    CHEN, RT
    RASTOGI, SC
    MULLEN, JR
    HAYES, SW
    COCHI, SL
    DONLON, JA
    WASSILAK, SG
    [J]. VACCINE, 1994, 12 (10) : 960 - 960
  • [23] Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)?
    McNeil, Michael M.
    Li, Rongxia
    Pickering, Susanne
    Real, Theresa M.
    Smith, Philip J.
    Pemberton, Michael R.
    [J]. VACCINE, 2013, 31 (24) : 2673 - 2679
  • [24] Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
    Sever, JL
    Brenner, AI
    Gale, AD
    Lyle, JM
    Moulton, LH
    Ward, BJ
    West, DJ
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (12) : 825 - 840
  • [25] Quantitative Vaccine Safety Signal Detection Techniques Using Vaccine Adverse Event Reporting System (VAERS)
    Liang, Huifang
    Sakaguchi, Motonobu
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 238 - 238
  • [26] Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013
    Moro, Pedro L.
    Harrington, Theresa
    Shimabukuro, Tom
    Cano, Maria
    Museru, Oidda I.
    Menschik, David
    Broder, Karen
    [J]. VACCINE, 2013, 31 (43) : 4984 - 4987
  • [27] Is the US's Vaccine Adverse Event Reporting System broken?
    Block, Jennifer
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 383
  • [28] The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS)
    Geier, David A.
    King, Paul G.
    Sykes, Lisa K.
    Geier, Mark R.
    [J]. MEDICAL SCIENCE MONITOR, 2012, 18 (02): : PH12 - PH17
  • [29] Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics impact
    Almadani, Ohoud A.
    Alshammari, Thamir M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 610 - 611
  • [30] Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact
    Almadani, Ohoud A.
    Alshammari, Thamir M.
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (12) : 1725 - 1735